239 related articles for article (PubMed ID: 30355451)
21. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
22. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
23. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Gossage L; Murtaza M; Slatter AF; Lichtenstein CP; Warren A; Haynes B; Marass F; Roberts I; Shanahan SJ; Claas A; Dunham A; May AP; Rosenfeld N; Forshew T; Eisen T
Genes Chromosomes Cancer; 2014 Jan; 53(1):38-51. PubMed ID: 24166983
[TBL] [Abstract][Full Text] [Related]
24. SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippel-Lindau protein ubiquitination and degradation.
Yin R; Liu S
Cancer Sci; 2021 Oct; 112(10):4100-4111. PubMed ID: 34339558
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus.
Roos FC; Roberts AM; Hwang II; Moriyama EH; Evans AJ; Sybingco S; Watson IR; Carneiro LA; Gedye C; Girardin SE; Ailles LE; Jewett MA; Milosevic M; Wilson BC; Bell JC; Der SD; Ohh M
EMBO Mol Med; 2010 Jul; 2(7):275-88. PubMed ID: 20623734
[TBL] [Abstract][Full Text] [Related]
26. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
27. Modeling Renal Cell Carcinoma in Mice:
Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
[TBL] [Abstract][Full Text] [Related]
28. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
[TBL] [Abstract][Full Text] [Related]
29. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
[TBL] [Abstract][Full Text] [Related]
30. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
31. NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α.
Gregg JL; Turner RM; Chang G; Joshi D; Zhan Y; Chen L; Maranchie JK
Cancer Res; 2014 Jul; 74(13):3501-3511. PubMed ID: 24755467
[TBL] [Abstract][Full Text] [Related]
32. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.
Karlo CA; Di Paolo PL; Chaim J; Hakimi AA; Ostrovnaya I; Russo P; Hricak H; Motzer R; Hsieh JJ; Akin O
Radiology; 2014 Feb; 270(2):464-71. PubMed ID: 24029645
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner.
Huang Q; Sun Y; Zhai W; Ma X; Shen D; Du S; You B; Niu Y; Huang CP; Zhang X; Chang C
Oncogene; 2020 Oct; 39(43):6677-6691. PubMed ID: 32943729
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
Vanharanta S; Shu W; Brenet F; Hakimi AA; Heguy A; Viale A; Reuter VE; Hsieh JJ; Scandura JM; Massagué J
Nat Med; 2013 Jan; 19(1):50-6. PubMed ID: 23223005
[TBL] [Abstract][Full Text] [Related]
35. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.
Wang SS; Gu YF; Wolff N; Stefanius K; Christie A; Dey A; Hammer RE; Xie XJ; Rakheja D; Pedrosa I; Carroll T; McKay RM; Kapur P; Brugarolas J
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16538-43. PubMed ID: 25359211
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
[TBL] [Abstract][Full Text] [Related]
37. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
38. Deficiency of the X-inactivation escaping gene
Zheng Q; Li P; Zhou X; Qiang Y; Fan J; Lin Y; Chen Y; Guo J; Wang F; Xue H; Xiong J; Li F
Theranostics; 2021; 11(18):8674-8691. PubMed ID: 34522206
[No Abstract] [Full Text] [Related]
39. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
[TBL] [Abstract][Full Text] [Related]
40. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]